Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.

Orizondo RA, Babcock CI, Fabiilli ML, Pavlovsky L, Fowlkes JB, Younger JG, Cook KE.

J Aerosol Med Pulm Drug Deliv. 2014 Oct;27(5):392-9. doi: 10.1089/jamp.2013.1058. Epub 2014 Jan 29.

2.

Effects of Emulsion Composition on Pulmonary Tobramycin Delivery During Antibacterial Perfluorocarbon Ventilation.

Orizondo RA, Fabiilli ML, Morales MA, Cook KE.

J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):251-9. doi: 10.1089/jamp.2015.1235. Epub 2016 Jan 7.

PMID:
26741303
3.

Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.

Beaulac C, Clément-Major S, Hawari J, Lagacé J.

Antimicrob Agents Chemother. 1996 Mar;40(3):665-9.

4.

Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.

Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G.

J Infect Dis. 2010 Nov 15;202(10):1585-92. doi: 10.1086/656788. Epub 2010 Oct 13.

PMID:
20942647
5.

Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.

Halwani M, Hebert S, Suntres ZE, Lafrenie RM, Azghani AO, Omri A.

Int J Pharm. 2009 May 21;373(1-2):141-6. doi: 10.1016/j.ijpharm.2009.02.001. Epub 2009 Feb 12.

PMID:
19429299
6.

Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.

Alhariri M, Omri A.

Antimicrob Agents Chemother. 2013 Jan;57(1):569-78. doi: 10.1128/AAC.01634-12. Epub 2012 Nov 12.

7.

The effect of electrical currents and tobramycin on Pseudomonas aeruginosa biofilms.

Jass J, Costerton JW, Lappin-Scott HM.

J Ind Microbiol. 1995 Sep;15(3):234-42.

PMID:
8519482
8.
9.

Sound waves effectively assist tobramycin in elimination of Pseudomonas aeruginosa biofilms in vitro.

Bandara HM, Harb A, Kolacny D Jr, Martins P, Smyth HD.

AAPS PharmSciTech. 2014 Dec;15(6):1644-54. doi: 10.1208/s12249-014-0200-1. Epub 2014 Aug 26.

10.

Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.

Price KE, Orazi G, Ruoff KL, Hebert WP, O'Toole GA, Mastoridis P.

PLoS One. 2015 Oct 27;10(10):e0141192. doi: 10.1371/journal.pone.0141192. eCollection 2015 Oct 27.

11.

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Parkins MD, Elborn JS.

Expert Rev Respir Med. 2011 Oct;5(5):609-22. doi: 10.1586/ers.11.56. Review.

PMID:
21955231
12.

Co-administration of aqueous ginseng extract with tobramycin stimulates the pro-inflammatory response and promotes the killing of Pseudomonas aeruginosa in the lungs of infected rats.

Alipour M, Omri A, Lui EM, Suntres ZE.

Can J Physiol Pharmacol. 2013 Nov;91(11):935-40. doi: 10.1139/cjpp-2013-0073. Epub 2013 Jun 27.

PMID:
24117261
13.

Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.

Al-Aloul M, Nazareth D, Walshaw M.

J Aerosol Med Pulm Drug Deliv. 2014 Aug;27(4):299-305. doi: 10.1089/jamp.2013.1055. Epub 2013 Nov 12.

PMID:
24219814
14.

Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model.

Cao B, Christophersen L, Thomsen K, Sønderholm M, Bjarnsholt T, Jensen PØ, Høiby N, Moser C.

J Antimicrob Chemother. 2015 Jul;70(7):2057-63. doi: 10.1093/jac/dkv058. Epub 2015 Mar 18.

PMID:
25786481
15.

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.

McCaughey G, McKevitt M, Elborn JS, Tunney MM.

J Cyst Fibros. 2012 May;11(3):163-72. doi: 10.1016/j.jcf.2011.11.003. Epub 2011 Dec 3.

16.
17.

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.

Pediatr Pulmonol. 2007 Apr;42(4):307-13.

PMID:
17352404
18.

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.

Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H.

Paediatr Drugs. 2007;9 Suppl 1:21-31.

PMID:
17536872
20.

Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).

Deacon J, Abdelghany SM, Quinn DJ, Schmid D, Megaw J, Donnelly RF, Jones DS, Kissenpfennig A, Elborn JS, Gilmore BF, Taggart CC, Scott CJ.

J Control Release. 2015 Jan 28;198:55-61. doi: 10.1016/j.jconrel.2014.11.022. Epub 2014 Dec 4.

PMID:
25481442

Supplemental Content

Support Center